Cristofanilli M, Slamon DJ, Ro J, et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. ESMO 2018, abstract LBA2_PR.
Synergetisch effect van radiotherapie + immuuntherapie bij NSCLC
mei 2021 | Immuuntherapie, Longoncologie, Radiotherapie